多重NNRTI耐药突变HIV-1克隆对多拉韦林的体外交叉耐药
本研究在10株临床来源的HIV-1感染性克隆及NL4-3定点突变株中检测多拉韦林的体外表型敏感性。尽管这些克隆均不携带IAS-USA多拉韦林主要耐药突变,但多拉韦林折叠变化值与其他NNRTI相当或更高,且随NNRTI耐药突变数目增加而显著上升(P=0.005)。结论提示基于IAS-USA简单列表可能低估复杂突变病毒对多拉韦林的耐药。
要点
- 无IAS-USA多拉韦林主要耐药突变时仍可检出显著交叉耐药。
- NNRTI耐药突变数目越多,多拉韦林FC值越高(P=0.005)。
- 仅凭IAS-USA列表评估多拉韦林耐药可能低估。
核心结论
- 携带复杂NNRTI突变模式的病毒即使无IAS-USA多拉韦林主要耐药突变,仍可对多拉韦林产生显著交叉耐药,基于IAS-USA简单列表可能低估耐药。
研究设计与样本
- 体外表型研究,检测10株临床来源感染性克隆及NL4-3定点突变株对多拉韦林的敏感性。
主要发现
- 单突变K103N和Y181C不损害多拉韦林敏感性(FC分别为1.4和1.8)。
- 单突变M230L和双突变K103N/Y181C降低多拉韦林活性(FC分别为7.6和4.9)。
- 多拉韦林FC值随NNRTI耐药突变数目增加而显著上升(P=0.005)。
- 携带4个和3个NNRTI耐药突变的克隆中分别有4/4和1/4的FC值>10。
- FC值与Stanford HIVdb和ANRS算法预测的敏感性相关(均P<0.001)。
临床怎么用
- 对携带多个NNRTI耐药突变的HIV-1,不应仅依据IAS-USA多拉韦林主要耐药突变列表判断多拉韦林敏感性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Doravirine is a recently licensed HIV-1 NNRTI with improved efficacy, pharmacokinetics and safety profile compared with efavirenz and limited cross-resistance with rilpivirine and etravirine. In this in vitro study, cross-resistance to doravirine was analysed in a representative panel of NNRTI-resistant clones. METHODS: In vitro phenotypic susceptibility to doravirine was assessed in 10 clinically derived infectious clones with intermediate- to high-level resistance to rilpivirine, etravirine, efavirenz and nevirapine, and in NL4-3 site-directed mutants harbouring K103N, Y181C, M230L or K103N/Y181C NNRTI mutations. RESULTS: Although none of the infectious clones harboured any of the major doravirine resistance-associated mutations (RAMs) included in the IAS-USA reference list, doravirine fold change (FC) values were comparable to or higher than those calculated for other NNRTIs, particularly etravirine and rilpivirine. As expected, single NNRTI mutations K103N and Y181C did not impair doravirine susceptibility (FC 1.4 and 1.8, respectively), while reduced activity was observed with the single M230L or double K103N/Y181C mutations (FC 7.6 and 4.9, respectively). Median FC values increased significantly with increasing numbers of NNRTI RAMs (P = 0.005) and were >10 in 4/4 and 1/4 clones harbouring four and three NNRTI RAMs, respectively. FC values correlated well with predicted susceptibility as inferred by Stanford HIV Drug Resistance Database (HIVdb) and ANRS algorithms (both P < 0.001). CONCLUSIONS: Substantial cross-resistance to doravirine was detected in NNRTI-resistant viruses harbouring complex mutational patterns, even in the absence of major IAS-USA doravirine RAMs. Therefore, based on the simple IAS-USA reference list, doravirine resistance may be underestimated in viruses harbouring multiple NNRTI mutations.
引用
- Saladini F, Giammarino F, Hosseini BA, et al. In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations. J Antimicrob Chemother. 2021. PMID: 32974670. doi:10.1093/jac/dkaa401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。